Preclinical study of Pseudomonas aeruginosa PcrV-CpG(K3)-SPG Vaccine

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H05008
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Sawa Teiji 京都府立医科大学, 医学(系)研究科(研究院), 教授 (10206013)
• Co-Investigator(Kenkyū-buntansha): 森山 潔 杏林大学, 医学部, 准教授 (10296717) ; 天谷 文昌 京都府立医科大学, 医学(系)研究科(研究院), 准教授 (60347466) ; 中屋 隆明 京都府立医科大学, 医学(系)研究科(研究院), 教授 (80271633)
• Co-Investigator(Renkei-kenkyūsha): Ishii Ken 国立研究開発法人医薬基盤研究所, 教授 (00448086)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 緑膿菌 / ワクチン / 三型分泌システム / PcrV / CpG oligonucleotide / 肺炎 / 動物モデル / 前臨床試験

Outline of Final Research Achievements

An effective vaccine against Pseudomonas aeruginosa would be hugely beneficial to people who are susceptible to the serious infections caused by it. Vaccination against PcrV of the P. aeruginosa type III secretion system is a potential prophylactic strategy for improving the incidence and poor prognosis of P. aeruginosa pneumonia. Here, the effect of nasal PcrV adjuvanted with CpG oligodeoxynucleotide (CpG) was investigated in an mouse model of P. aeruginosa pneumonia. In vaccinated mice, the significant increase in PcrV-specific titers was detected. Vaccinated mice with nasal PcrV-CpG vaccine survived from a lethal P. aeruginosa pneumonia. Overall, our data show that the nasal PcrV-CpG vaccine has potential efficacy for clinical application against P. aeruginosa pneumonia.

Free Research Field

集中治療医学、予防医学